Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

C-Bridge Raising $650 Million for Third China Healthcare PE Fund

publication date: Jan 29, 2018

Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million. Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million. C-Bridge focuses on PE capital because it believes later-stage companies are currently the most promising investment sector in China healthcare. The company emphasizes China investments, but considers itself a global investor. With the new fund, C-Bridge will have $1.35 billion in assets under management. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital